FLCCC to Merck: Data Shows Ivermectin’s Strong Efficacy Against COVID-19

FLCCC to Merck: Data Shows Ivermectin’s Strong Efficacy Against COVID-19

The Front Line COVID-19 Critical Care Alliance (FLCCC) has issued a public statement in response to a press release issued by Merck last week.

When the FLCCC Alliance reviewed the Merck release of February 4, 2021— which discounted the efficacy of ivermectin for the prevention and treatment of COVID-19— they were stunned by the fact that Merck provided no scientific data to support their conclusion. Additionally, the company’s absolute disregard for the most current medical evidence is an evidentiary indictment of their uncorroborated position. 

Furthermore, the FLCCC—with a lifesaving mission inspired by the imperatives to “put patients first” and to “follow the science”—believes that the pharmaceutical giant’s press release will cause governments, health authorities, medical providers, business leaders, and citizens to retreat from pursuing a medical agent that, according to our recent peer-reviewed and accepted publication to the highly regarded Frontiers in Pharmacology, has been proven to be an effective and globally available agent to prevent and treat every phase of COVID-19 disease. It is critical to note that with supplies of the vaccines running short—especially in low-income countries—people will be left to believe that there are no safe therapeutic alternatives. That falsehood will certainly result in rising case counts and mounting death tolls.

We fully realize that the capacity of our voice to shout this dire warning to the world over is a whisper when compared to the global echo of Merck. But as highly published and well-known Critical Care physicians at the bedside who have developed two lifesaving protocols for this disease, we are compelled to speak out for patients the world over who deserve to know that they and their loved ones do not have to die from COVID-19 given the known efficacy of ivermectin.

About the Front Line COVID-19 Critical Care Alliance

The FLCCC Alliance was organized in March, 2020 by a group of highly published, world renowned Critical Care physician/scholars – with the academic support of allied physicians from around the world – to research and develop lifesaving protocols for the prevention and treatment of COVID-19 in all stages of illness. Their MATH+ Hospital Treatment Protocol – introduced in March, 2020, has saved thousands who were critically ill with COVID-19. Now, the FLCCC’s new I-Mask+ Prophylaxis and Early At-Home Outpatient Protocol with Ivermectin has been released – and is a potential solution to the global pandemic.  

Call to Action: For more information contact [email protected].

Responses

  1. Merck’s press release is at odds with the NIH guidelines. They are recommending unethical behavior by physicians, making them unethical.
    Why do I say unethical?
    Physicians must use the best available data, even if imperfect. The best available data at end of Jan 2021 is the meta-analysis funded by the WHO and carried out by Dr. Andrew Hill’s group in Liverpool. It concluded that evidence of moderate quality suggests that ivermectin shortens time to viral clearance, time to clinical recovery, duration of hospitalization and SURVIVAL of hospitalized patients by 83%. It seems more effective at higher doses and given on multiple days (no surprise). The drug is inexpensive and is as safe as any commonly prescribed medication. To fail to prescribe it for a confirmed case of Covid-19 is unethical.
    That being said, we eagerly await the results of additional trials with larger numbers of patients, and perhaps of better design or reporting. The "science" could change as new data arrive.

  2. Yes, what Trevor said. Let’s throw shade at Ivermectin, because our drug molnupiravir (MK-4482, EIDD-2801) is in trials with nearly a year to go. I looked into 2801, and it appears extremely effective, perhaps 20 times better and twice as fast as Ivermectin. Developed at Emory U, then worked on by Ridgeback Therapeutics, passed phase 1 in UK as part of AGILE project, did phase 2, was acquired by Merck who went directly to Phase 2/3 without releasing results. This may be a wonder drug in the making, but it will take quite a few more months to determine proper dosage and long term safety. So I’d say go with the Ivermectin now if you need it or as a prophylaxis. It’s not like this virus is going away, ever. You fight a fire with what you have now. You don’t let the house burn down while waiting for Wonder Water to show up.